Sanofi (SAN)

Index:

CAC 40

  97.11
   
  • Change Today:
     -1.60
  • 52 Week High:  105.76
  • 52 Week Low:  83.65
  • Currency: Euro
  • Shares Issued: 13.45m
  • Volume: 2,710,235
  • Market Cap:  1,306.13m
  • Beta: 0.45

AstraZeneca, Sanofi infant respiratory treatment gets US approval

By Frank Prenesti

Date: Tuesday 18 Jul 2023

LONDON (ShareCast) - (Sharecast News) - AstraZeneca and Sanofi's Beyfortus drug has been approved in the US for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants, the two companies said on Tuesday.




The treatment is given to those born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. Beyfortus will be available in the US ahead of the upcoming 2023-2024 RSV season, they added.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Sanofi Market Data

Currency Euro
Share Price   97.11
Change Today   -1.60
% Change -1.62 %
52 Week High  105.76
52 Week Low  83.65
Volume 2,710,235
Shares Issued 13.45m
Market Cap  1,306.13m
Beta 0.45

What The Brokers Say

Strong Buy 12
Buy 8
Neutral 5
Sell 0
Strong Sell 1
Total 26
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Trades for 31-Oct-2024

Time Volume / Share Price
17:35 335 @  97.11
17:35 100 @  97.11
17:35 100 @  97.11
17:35 100 @  97.11
17:35 100 @  97.11

Top of Page